<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font6" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font7" size="9" family="GillSans,BoldItalic" color="#000000"/>
<text top="41" left="55" width="122" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Medical Immunology 2006, 5 :1<i>Medical Immunology</i></text>
<text top="41" left="384" width="170" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.medimmunol.com/content/5/1/1</text>
<text top="756" left="503" width="51" height="10" font="font1" id="p1_t3" reading_order_no="106" segment_no="15" tag_type="text">Page 4 of 14<b>5</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="107" segment_no="16" tag_type="text">(page number not for citation purposes)</text>
<text top="84" left="55" width="241" height="13" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">and TGF β 1 (10 ng/ml)(Peprotech) for one week. Differ-</text>
<text top="96" left="55" width="241" height="13" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">entiated Langerhans cells were matured with 1 μ g/ml Pep-</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">tidoglycan (Sigma) overnight. Cells were pulsed with<i>(page number not for citation purposes)</i></text>
<text top="120" left="55" width="241" height="13" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">HIV-1 peptide pools (10 μ M total) for 3 h and irradiated</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">(3000 rad). Fresh donor PBMC were prepared by Ficoll-</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">Paque (Amersham Biosciences) centrifugation. Donor</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">PBMC were plated at a density of 10 7 cells/ml together</text>
<text top="168" left="55" width="241" height="10" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">with 5 × 10 4 /ml peptide loaded irradiated donor Langer-</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">hans cells in 24 well culture plates in complete DMEM</text>
<text top="190" left="55" width="241" height="13" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">medium with 10 μ M HIV-1 peptide pools. Cultures were</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">fed with 10 u/ml IL-2 (BD biosciences) five days after</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">stimulation and re-stimulated with peptide loaded irradi-</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">ated (3000 rads) fresh donor PMBC every week. Replicate</text>
<text top="237" left="55" width="241" height="13" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">96 well plates were pulsed with 1 μ Ci per well 3 H Thymi-</text>
<text top="251" left="55" width="241" height="9" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">dine after 4 days of culture, harvested after 18 h, and 3 H</text>
<text top="261" left="55" width="241" height="13" font="font4" id="p1_t20" reading_order_no="17" segment_no="2" tag_type="text">Thymidine incorporation was detected using a β Counter</text>
<text top="275" left="55" width="108" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="2" tag_type="text">(Perkin Elmer 1450 LSC).</text>
<text top="298" left="55" width="53" height="9" font="font7" id="p1_t22" reading_order_no="19" segment_no="5" tag_type="title">CTL analysis</text>
<text top="309" left="55" width="241" height="10" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">A0201 + TAP- deficient T2 hybridoma target cells (ATCC)</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">or A2 supertype transfected 721.221 cell lines were plated</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">at a density of 10 6 cells/ml in 24 well plates. Cells were</text>
<text top="343" left="55" width="241" height="13" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">pulsed with 10 μ M A0201-restricted HIV-1 peptide pool</text>
<text top="355" left="55" width="241" height="13" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">or 10 μ M A0201-restricted HTLV-TAX as negative control</text>
<text top="369" left="55" width="241" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">peptide for 18 hours at 37°C. Cells were washed twice</text>
<text top="380" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="6" tag_type="text">with DMEM media (20% fetal calf serum, L-glutamine (2</text>
<text top="390" left="55" width="241" height="13" font="font4" id="p1_t30" reading_order_no="27" segment_no="6" tag_type="text">mM), penicillin (100 U/ml), streptomycin (100 μ g/ml),</text>
<text top="402" left="55" width="241" height="13" font="font4" id="p1_t31" reading_order_no="28" segment_no="6" tag_type="text">2-ME (50 μ M). (DMEM media). and pulsed with 100 μ C</text>
<text top="415" left="55" width="241" height="10" font="font4" id="p1_t32" reading_order_no="29" segment_no="6" tag_type="text">of 51 Cr for 90 minutes at 37°C. Target cells were washed</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="6" tag_type="text">three times with serum free OptiMEM media (Gibco) to</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="6" tag_type="text">remove excess 51 Cr and plated with sorted HIV-1 specific</text>
<text top="450" left="55" width="241" height="10" font="font4" id="p1_t35" reading_order_no="32" segment_no="6" tag_type="text">CD8 + T cells at 30:1, 10:1, 3:1 and 1:1 ratios. After four</text>
<text top="460" left="55" width="241" height="13" font="font4" id="p1_t36" reading_order_no="33" segment_no="6" tag_type="text">hours of incubation 50 μ l of culture supernatant were</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="6" tag_type="text">mixed with liquid scintillation cocktail (Perkin Elmer</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="6" tag_type="text">Optiphase supermix) and analyzed for 51 Cr release using</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="6" tag_type="text">a Luminescence Counter (Perkin Elmer 1450 LSC). Per-</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="6" tag_type="text">cent specific chromium release was calculated using the</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="6" tag_type="text">formula [(Experimental release- spontaneous release)/</text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="6" tag_type="text">(maximum release in 5% Triton-x100- spontaneous</text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="6" tag_type="text">release)]. To analyze CTL responses to naturally processed</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="6" tag_type="text">HIV-1 epitopes, TAP sufficient T1 hybridoma target cells</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="6" tag_type="text">T1 (A0201+, B5101 + , CD4 + ) were infected with 0.5 MOI<i><b>CTL analysis</b></i></text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="6" tag_type="text">HIV-IIIB per cell for 3 hours. Cells were washed and plated</text>
<text top="591" left="55" width="241" height="10" font="font4" id="p1_t47" reading_order_no="44" segment_no="6" tag_type="text">at a density of 10 6 /ml in DMEM media. 2–3 days later,</text>
<text top="603" left="55" width="241" height="10" font="font4" id="p1_t48" reading_order_no="45" segment_no="6" tag_type="text">HIV-IIIB infected T1 cells were used in 51 Cr release assay</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="6" tag_type="text">as described above. Intracellular p24 staining by FACS was</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="6" tag_type="text">used to demonstrate that essentially all target cells were</text>
<text top="639" left="55" width="75" height="9" font="font4" id="p1_t51" reading_order_no="48" segment_no="6" tag_type="text">HIV-IIIB-infected.</text>
<text top="660" left="55" width="209" height="13" font="font5" id="p1_t52" reading_order_no="49" segment_no="11" tag_type="title">IFN γ -ELISPOT assay on HIV-1 infected donor cells</text>
<text top="674" left="55" width="242" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="12" tag_type="text">CD8 + T-cell responses to pools of HIV-1 epitopes were</text>
<text top="684" left="55" width="241" height="13" font="font4" id="p1_t54" reading_order_no="51" segment_no="12" tag_type="text">quantified by gamma interferon (IFN- γ ) ELISpot assay as</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="12" tag_type="text">follows. Peripheral blood mononuclear cells (PBMC) iso-</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="12" tag_type="text">lated from HIV-1 infected patients were plated at 100,000</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="12" tag_type="text">per well with peptide pools at a final concentration of 10</text>
<text top="84" left="313" width="241" height="13" font="font5" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">μ M in anti-interferon gamma mAb 1-D1K (Mabtech,</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">Stockholm, Sweden) coated polyvinylidene 96-well plates</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">(Millipore.MA) and processed as previously described</text>
<text top="122" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">[21]. For each individual peptide, the assay was run in</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">triplicate. Negative and positive controls were obtained by</text>
<text top="145" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="3" tag_type="text">incubating individual PBMC with medium alone (nega-</text>
<text top="157" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="3" tag_type="text">tive control) and phytohemagglutinin (PHA) as a positive</text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="3" tag_type="text">control for naive patients. For the assessment of general</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="3" tag_type="text">immunocompetence of HIV-1 infected patients, a CEF</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="3" tag_type="text">peptide pool was used as an internal positive control. The</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="3" tag_type="text">CEF pool consists of optimal T cell epitopes for CMV/EBV</text>
<text top="216" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="3" tag_type="text">and Influenza viruses provided by the NIH reagent pro-</text>
<text top="228" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="3" tag_type="text">gram. Only HIV-1 patients whose blood yielded positive</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="3" tag_type="text">CEF and/or PHA responses were chosen as subjects for the</text>
<text top="251" left="313" width="58" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="3" tag_type="text">present study.</text>
<text top="272" left="313" width="241" height="13" font="font4" id="p1_t73" reading_order_no="70" segment_no="4" tag_type="text">The number of specific IFN- γ secreting T cells was deter-</text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="4" tag_type="text">mined with an automated ELISPOT reader (AID, Strass-</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="4" tag_type="text">berg, Germany), calculated by subtracting the average</text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="4" tag_type="text">negative control value and expressed as the number of</text>
<text top="321" left="313" width="241" height="10" font="font4" id="p1_t77" reading_order_no="74" segment_no="4" tag_type="text">spot-forming cells (SFC) per 10 6 input cells. Negative con-</text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="4" tag_type="text">trols were approximately 50 SFC per 10 6 input cells for</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="4" tag_type="text">HIV-1 infected patients and around 40 for naïve subjects.</text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="4" tag_type="text">A response was considered positive if there were 50 SFC</text>
<text top="368" left="313" width="241" height="10" font="font4" id="p1_t81" reading_order_no="78" segment_no="4" tag_type="text">per 10 6 input cells and the activity was at least three times</text>
<text top="380" left="313" width="172" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="4" tag_type="text">as great as the mean background activity.</text>
<text top="401" left="313" width="241" height="13" font="font5" id="p1_t83" reading_order_no="80" segment_no="7" tag_type="title">IFN γ – production on HIV-1 specific T cell lines generated</text>
<text top="416" left="313" width="75" height="9" font="font7" id="p1_t84" reading_order_no="81" segment_no="7" tag_type="title">from naive donors</text>
<text top="427" left="313" width="241" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="text">HIV-1 peptide pool-specific T cell lines were generated as</text>
<text top="439" left="313" width="241" height="9" font="font4" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="text">described above. Two weeks after the second stimulation,</text>
<text top="451" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="8" tag_type="text">25,000 per well HIV-1 specific T cells were plated into</text>
<text top="463" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="8" tag_type="text">anti-interferon gamma mAB 1-D1K (Mabtech) coated</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="8" tag_type="text">polyvinylidene 96-well plates (Millipore) with 25,000 per</text>
<text top="484" left="313" width="241" height="13" font="font4" id="p1_t90" reading_order_no="87" segment_no="8" tag_type="text">well irradiated donor PBMCs and stimulated with 10 μ M</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="8" tag_type="text">of each HIV-1 peptide pool. Plates were processed and</text>
<text top="510" left="313" width="226" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="8" tag_type="text">spot forming cells were calculated as described above.</text>
<text top="533" left="313" width="109" height="9" font="font7" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="title">HLA-A 0201-binding assay</text>
<text top="544" left="313" width="241" height="10" font="font4" id="p1_t94" reading_order_no="91" segment_no="10" tag_type="text">A0201 + TAP- deficient T2 hybridoma cells (ATCC) were</text>
<text top="556" left="313" width="241" height="10" font="font4" id="p1_t95" reading_order_no="92" segment_no="10" tag_type="text">plated at a density of 10 6 cells/ml in 24 well plates. Cells</text>
<text top="566" left="313" width="241" height="13" font="font4" id="p1_t96" reading_order_no="93" segment_no="10" tag_type="text">were pulsed with 10 μ M A0201 restricted HIV-1B pep-</text>
<text top="578" left="313" width="241" height="13" font="font4" id="p1_t97" reading_order_no="94" segment_no="10" tag_type="text">tides, 10 μ M A0201restricted HTLV-TAX (LLFGYPVYV)</text>
<text top="590" left="313" width="241" height="13" font="font4" id="p1_t98" reading_order_no="95" segment_no="10" tag_type="text">positive control peptide and 5 μ g/ml β 2 microglobulin</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="10" tag_type="text">(BD biosciences) for 18 hours at 37°C in serum free AIM5</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="10" tag_type="text">media (Gibco). A0201 expression was determined by flow</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="10" tag_type="text">cytometry (FACSAria) using FITC-conjugated BB7.2 mAb</text>
<text top="639" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">(BDbiosciences). Mean cell fluorescence (MCF) intensi-</text>
<text top="651" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">ties were normalized to HTLV-TAX positive control pep-</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">tide using the formula [(MCF.sample- MCF.control)/</text>
<text top="674" left="313" width="136" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">(MCF.HTLV-TAT-MCF.control)].</text>
<text top="698" left="313" width="67" height="9" font="font7" id="p1_t106" reading_order_no="103" segment_no="13" tag_type="title">DimerX staining</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="14" tag_type="text">A2:Ig fusion protein DimerX (BD Biosciences) was passive<i><b>IFN</b></i></text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t108" reading_order_no="105" segment_no="14" tag_type="text">loaded with individual A0201 restricted HIV-1B peptides</text>
</page>
</pdf2xml>
